title: Outcomes from intracerebral hemorrhage among patients pre-treated with statins.
abstract: OBJECTIVE
  3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, have been associated with improved clinical outcomes after ischemic stroke and subarachnoid hemorrhage, but with an increased risk of incidental spontaneous intracerebral hemorrhage (ICH). We investigated whether the statin use before ICH, was associated with functional independence, 90 days after treatment.
  
  
  METHODS
  We analyzed 124 consecutive ICH patients with 90-day outcome data who were enrolled in a prospective cohort study between 2006 and 2009. Eighty-three patients were included in this study. Among ICH survivors, univariate Cox regression models and Kaplan-Meier plots were used to determine subject characteristics that were associated with an increased risk of recurrence. Statin usage was determined through interviewing the patient at the time of ICH and confirmed by reviewing their medical records. Independent status was defined as Glasgow Outcome Scale grades 4 or 5.
  
  
  RESULTS
  Statins were used by 20 out of 83 patients (24%) before ICH onset. There was no effect from pre-ICH statin use on functional independence rates (28% versus 29%, P=0.84) or mortality (46% versus 45%, P=0.93).
  
  
  CONCLUSIONS
  Pre-ICH statin use is not associated with changes to ICH functional outcome or mortality.
authors.affiliation: Neurosurgery Service, Hospital Ipiranga, SUS, São Paulo SP, Brazil. frromero@ig.com.br
authors.forename: Flávio Ramalho
authors.initials: FR
authors.lastname: Romero
authors.forename: Eduardo de Freitas
authors.initials: Ede F
authors.lastname: Bertolini
authors.forename: Vanessa Nogueira
authors.initials: VN
authors.lastname: Veloso
authors.forename: Leandro
authors.initials: L
authors.lastname: Venturini
authors.forename: Eberval G
authors.initials: EG
authors.lastname: Figueiredo
mesh_terms: D000368:Aged; D002543:Cerebral Hemorrhage / Q000188:drug therapy* / Q000401:mortality; D004185:Disability Evaluation; D005500:Follow-Up Studies; D023261:Glasgow Outcome Scale; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D011379:Prognosis; D020127:Recovery of Function / Q000187:drug effects*; D012189:Retrospective Studies
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors